| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [2] |
Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma[J]. Radiology, 2000, 216(3): 698-703. DOI: 10.1148/radiology.216.3.r00se24698.
|
| [3] |
Shuto T, Hirohashi K, Kubo S, et al. Treatment of adrenal metastases after hepatic resection of a hepatocellular carcinoma[J]. Dig Surg, 2001, 18(4): 294-297. DOI: 10.1159/000050155.
|
| [4] |
Elmoghazy W, Ahmed K, Vijay A, et al. Hepatocellular carcinoma in a rapidly growing community: epidemiology, clinico-pathology and predictors of extrahepatic metastasis[J]. Arab J Gastroenterol, 2019, 20(1): 38-43. DOI: 10.1016/j.ajg.2019.01.006.
|
| [5] |
Yan B, Bai DS, Zhang C, et al. Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: a retrospective cohort study in the SEER database[J]. Int J Surg, 2020, 80: 94-100. DOI: 10.1016/j.ijsu.2020.06.018.
|
| [6] |
Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors[J]. Cancer, 2011, 117(19): 4475-4483. DOI: 10.1002/cncr.25960.
|
| [7] |
Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33(2): 347-354. DOI: 10.1111/jgh.13843.
|
| [8] |
Choi SH, Lee BM, Kim J, et al. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a phase Ⅱ study[J]. J Hepatol, 2024, 81(1): 84-92. DOI: 10.1016/j.jhep.2024.03.003.
|
| [9] |
Wang L, Ye G, Zhan C, et al. Clinical factors predictive of a better prognosis of pulmonary metastasectomy for hepatocellular carcinoma[J]. Ann Thorac Surg, 2019, 108(6): 1685-1691. DOI: 10.1016/j.athoracsur.2019.06.086.
|
| [10] |
Hiraki T, Kanazawa S. Lung radiofrequency ablation: potential as a therapy to oligometastasis and oligorecurrence[J]. Pulm Med, 2012, 2012: 196173. DOI: 10.1155/2012/196173.
|
| [11] |
Mansur A, Garg T, Camacho JC, et al. Image-guided percutaneous and transarterial therapies for primary and metastatic lung cancer[J]. Technol Cancer Res Treat, 2023, 22: 15330338231164193. DOI: 10.1177/15330338231164193.
|
| [12] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508. DOI: 10.1200/JCO.2012.44.5643.
|
| [13] |
Pelizzaro F, Sammarco A, Dadduzio V, et al. Capecitabine in advanced hepatocellular carcinoma: a multicenter experience[J]. Dig Liver Dis, 2019, 51(12): 1713-1719. DOI: 10.1016/j.dld.2019.06.015.
|
| [14] |
Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: a retrospective, multicenter study[J]. J BUON, 2019, 24(5): 1956-1963.
|
| [15] |
Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response[J]. Cancer, 2009, 115(2): 428-436. DOI: 10.1002/cncr.24029.
|
| [16] |
Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9): 1276-1282. DOI: 10.1001/jamaoncol.2019.1478.
|
| [17] |
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051-2058. DOI: 10.1016/S0140-6736(18)32487-5.
|
| [18] |
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase Ⅱ randomized trial[J]. J Clin Oncol, 2020, 38(25): 2830-2838. DOI: 10.1200/JCO.20.00818.
|
| [19] |
Harrow S, Palma DA, Olson R, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes[J]. Int J Radiat Oncol Biol Phys, 2022, 114(4): 611-616. DOI: 10.1016/j.ijrobp.2022.05.004.
|
| [20] |
Kim TH, Nam TK, Yoon SM, et al. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04)[J]. Cancers, 2022, 14(23): 5848. DOI: 10.3390/cancers14235848.
|
| [21] |
Kato H, Yoshida H, Taniguch H, et al. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(46): 13101-13112. DOI: 10.3748/wjg.v21.i46.13101.
|
| [22] |
Jo IY, Park HC, Kim ES, et al. Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08)[J]. Jpn J Clin Oncol, 2022, 52(6): 616-622. DOI: 10.1093/jjco/hyac028.
|
| [23] |
Bae SH, Park HC, Lim DH, et al. Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012, 82(4): e603-e607. DOI: 10.1016/j.ijrobp.2011.09.053.
|
| [24] |
Park JH, Yoon SM, Lim YS, et al. Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2013, 28(10): 1638-1642. DOI: 10.1111/jgh.12249.
|
| [25] |
Jang JW, Kay CS, You CR, et al. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases[J]. Int J Radiat Oncol, 2009, 74(2): 412-418. DOI: 10.1016/j.ijrobp.2008.08.034.
|
| [26] |
Jiang W, Zeng ZC, Zhang JY, et al. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma[J]. Clin Exp Metastasis, 2012, 29(3): 197-205. DOI: 10.1007/s10585-011-9442-4.
|
| [27] |
Lin G, Xiao H, Zeng Z, et al. Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma[J]. Radiother Oncol, 2017, 123(2): 246-250. DOI: 10.1016/j.radonc.2017.02.015.
|
| [28] |
Wang F, Fan S, Shi Q, et al. Comparison of clinical outcomes between cone beam CT-guided thermal ablation and helical tomotherapy in pulmonary metastases from hepatocellular carcinoma[J]. Front Oncol, 2022, 12: 947284. DOI: 10.3389/fonc.2022.947284.
|
| [29] |
Zhang L, Chen LH, Wang J, et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629. DOI: 10.1016/j.crad.2014.01.024.
|
| [30] |
Yang C, He C, Yu S, et al. Effects of iodine-125 seed brachytherapy on patients with heterochronous pulmonary metastasis from hepatocellular carcinoma: a propensity score matching study[J]. J Cancer Res Ther, 2023, 19(4): 957-963. DOI: 10.4103/jcrt.jcrt_519_22.
|
| [31] |
Zhang F, Wang J, Guo J, et al. Chinese expert consensus workshop report: guideline for permanent iodine-125 seeds implantation of primary and metastatic lung tumors (2020 edition)[J]. J Cancer Res Ther, 2020, 16(7): 1549-1554. DOI: 10.4103/jcrt.JCRT_1096_20.
|
| [32] |
Li C, Zhang F, Zhang W, et al. Feasibility of iodine-125 brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2010, 136(11): 1633-1640. DOI: 10.1007/s00432-010-0821-z.
|
| [33] |
Shen J, Wang LF, Zou ZY, et al. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2017, 23(29): 5395-5404. DOI: 10.3748/wjg.v23.i29.5395.
|
| [34] |
Lee BM, Seong J. Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report[J]. J Liver Cancer, 2021, 21(2): 163-168. DOI: 10.17998/jlc.2021.08.06.
|
| [35] |
Kim JS, You CR, Jang JW, et al. Application of helical tomotherapy for two cases of advanced hepatocellular carcinoma[J]. Korean J Intern Med, 2011, 26(2): 201-206. DOI: 10.3904/kjim.2011.26.2.201.
|
| [36] |
Sun T, He J, Zhang S, et al. Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma[J]. Oncotarget, 2016, 7(30): 48586-48599. DOI: 10.18632/oncotarget.9374.
|
| [37] |
Kim HJ, Park S, Kim KJ, et al. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy[J]. Radiother Oncol, 2018, 129(1): 130-135. DOI: 10.1016/j.radonc.2017.11.027.
|
| [38] |
Zhuang Y, Chen Y, Du S, et al. Safety and efficacy of hypofractionated radiotherapy combined with tyrosine kinase inhibitors in patients with lung metastases after liver transplantation for hepatocellular carcinoma[J]. Int J Radiat Oncol, 2023, 117(2): e360. DOI: 10.1016/j.ijrobp.2023.06.2448.
|